Trial Profile
A randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in treatment-naive patients with PDL1-positive stage IV Non-Small Cell Lung Cancer (NSCLC) after Nivolumab-Ipilimumab induction treatment
Status:
Suspended
Phase of Trial:
Phase III
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms DICIPLE
- 28 Sep 2023 Planned End Date changed from 1 May 2023 to 1 Dec 2024.
- 28 Sep 2023 Planned primary completion date changed from 1 May 2023 to 1 Nov 2023.
- 06 Jun 2023 Primary endpoint (Progression Free Survival (PFS1)) has not been met, according to Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.